![Frontiers | Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients Frontiers | Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients](https://www.frontiersin.org/files/Articles/1020058/fonc-12-1020058-HTML-r1/image_m/fonc-12-1020058-g001.jpg)
Frontiers | Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
![Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067 | PharmacoEconomics - Open Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067 | PharmacoEconomics - Open](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs41669-022-00348-0/MediaObjects/41669_2022_348_Fig2_HTML.png)
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067 | PharmacoEconomics - Open
![Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial | Nature Medicine Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02189-0/MediaObjects/41591_2022_2189_Fig2_HTML.png)
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial | Nature Medicine
![ESMO 2021: Nivolumab in Combination With Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients With Advanced RCC: A Randomized Phase II Trial (PRISM) ESMO 2021: Nivolumab in Combination With Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients With Advanced RCC: A Randomized Phase II Trial (PRISM)](https://www.urotoday.com/images/com-doc-importer/18-esmo-2021/esmo-2021-nivolumab-in-combination-with-alternatively-scheduled-ipilimumab-in-first-line-treatment-of-patients-with-advanced-rcc-a-randomized-phase-ii-trial-prism/image-0.jpg)
ESMO 2021: Nivolumab in Combination With Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients With Advanced RCC: A Randomized Phase II Trial (PRISM)
![JL413. Management of Gastrointestinal Adverse Events (AEs) Associated With Nivolumab and Ipilimumab Combination Therapy in Solid Tumors - JADPRO JL413. Management of Gastrointestinal Adverse Events (AEs) Associated With Nivolumab and Ipilimumab Combination Therapy in Solid Tumors - JADPRO](https://www.advancedpractitioner.com/media/209223/JADPRO_91_413-tbl01.jpg)
JL413. Management of Gastrointestinal Adverse Events (AEs) Associated With Nivolumab and Ipilimumab Combination Therapy in Solid Tumors - JADPRO
![Overall survival (OS) from the start of the first course of ipi/nivo... | Download Scientific Diagram Overall survival (OS) from the start of the first course of ipi/nivo... | Download Scientific Diagram](https://www.researchgate.net/publication/355660625/figure/fig1/AS:1085010627039237@1635698100329/Overall-survival-OS-from-the-start-of-the-first-course-of-ipi-nivo-A-and-from-the.png)
Overall survival (OS) from the start of the first course of ipi/nivo... | Download Scientific Diagram
![Cancers | Free Full-Text | Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study Cancers | Free Full-Text | Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study](https://pub.mdpi-res.com/cancers/cancers-14-02293/article_deploy/html/images/cancers-14-02293-g004.png?1654078871)
Cancers | Free Full-Text | Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
![Kam Zaki on X: "Updated phase III Checkmate 227 results showed ongoing OS benefit of ipilimumab/nivolumab combination over chemotherapy irrespective of PDL1 status as 1L Rx of metastatic NSCLC, median DOR (months) Kam Zaki on X: "Updated phase III Checkmate 227 results showed ongoing OS benefit of ipilimumab/nivolumab combination over chemotherapy irrespective of PDL1 status as 1L Rx of metastatic NSCLC, median DOR (months)](https://pbs.twimg.com/media/EZRbkTgX0AAEtiu.jpg:large)
Kam Zaki on X: "Updated phase III Checkmate 227 results showed ongoing OS benefit of ipilimumab/nivolumab combination over chemotherapy irrespective of PDL1 status as 1L Rx of metastatic NSCLC, median DOR (months)
![Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma | Nature Communications Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-26472-9/MediaObjects/41467_2021_26472_Fig1_HTML.png)
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma | Nature Communications
![Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma | Experimental Hematology & Oncology | Full Text Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma | Experimental Hematology & Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs40164-019-0138-9/MediaObjects/40164_2019_138_Fig4_HTML.png)